December 23, 2022 - Biospace reports - 2022 M&A activity in the life sciences sector failed to meet expectations, but Amgen’s recent $26.4 million buy-out of Horizon Therapeutics may be a sign of bigger things to come. 

PwC certainly thinks so, predicting a total deal value in the $225 billion to $275 billion range across all subsectors. The firm credits this anticipated upswing to a somewhat stabilized economic outlook, a need to close medium-term pipeline gaps, the resolution of the U.S. midterm elections and a better understanding of the impacts of the Inflation Reduction Act.

PwC predicts:

  • An average deal size of between $5 billion and $15 billion
  • A focus on oncology and immunology
  • A secondary focus on CNS, cardiovascular and vaccines
  • A significant premium on therapeutic area leadership
https://www.biospace.com/article/biospace-s-top-biopharma-m-and-a-candidates-for-2023/